Cargando…
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Much thought has been given to the impact of Amyloid Beta, Tau and Alpha-Synuclein in the development of Alzheimer's disease (AD) and Parkinson's disease (PD), yet the clinical failures of the recent decades indicate that there are further pathological mechanisms at work. Indeed, besides a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767977/ https://www.ncbi.nlm.nih.gov/pubmed/33381011 http://dx.doi.org/10.3389/fnins.2020.614828 |
_version_ | 1783629080690688000 |
---|---|
author | Reich, Niklas Hölscher, Christian |
author_facet | Reich, Niklas Hölscher, Christian |
author_sort | Reich, Niklas |
collection | PubMed |
description | Much thought has been given to the impact of Amyloid Beta, Tau and Alpha-Synuclein in the development of Alzheimer's disease (AD) and Parkinson's disease (PD), yet the clinical failures of the recent decades indicate that there are further pathological mechanisms at work. Indeed, besides amyloids, AD and PD are characterized by the culminative interplay of oxidative stress, mitochondrial dysfunction and hyperfission, defective autophagy and mitophagy, systemic inflammation, BBB and vascular damage, demyelination, cerebral insulin resistance, the loss of dopamine production in PD, impaired neurogenesis and, of course, widespread axonal, synaptic and neuronal degeneration that leads to cognitive and motor impediments. Interestingly, the acylated form of the hormone ghrelin has shown the potential to ameliorate the latter pathologic changes, although some studies indicate a few complications that need to be considered in the long-term administration of the hormone. As such, this review will illustrate the wide-ranging neuroprotective properties of acylated ghrelin and critically evaluate the hormone's therapeutic benefits for the treatment of AD and PD. |
format | Online Article Text |
id | pubmed-7767977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77679772020-12-29 Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease Reich, Niklas Hölscher, Christian Front Neurosci Neuroscience Much thought has been given to the impact of Amyloid Beta, Tau and Alpha-Synuclein in the development of Alzheimer's disease (AD) and Parkinson's disease (PD), yet the clinical failures of the recent decades indicate that there are further pathological mechanisms at work. Indeed, besides amyloids, AD and PD are characterized by the culminative interplay of oxidative stress, mitochondrial dysfunction and hyperfission, defective autophagy and mitophagy, systemic inflammation, BBB and vascular damage, demyelination, cerebral insulin resistance, the loss of dopamine production in PD, impaired neurogenesis and, of course, widespread axonal, synaptic and neuronal degeneration that leads to cognitive and motor impediments. Interestingly, the acylated form of the hormone ghrelin has shown the potential to ameliorate the latter pathologic changes, although some studies indicate a few complications that need to be considered in the long-term administration of the hormone. As such, this review will illustrate the wide-ranging neuroprotective properties of acylated ghrelin and critically evaluate the hormone's therapeutic benefits for the treatment of AD and PD. Frontiers Media S.A. 2020-12-14 /pmc/articles/PMC7767977/ /pubmed/33381011 http://dx.doi.org/10.3389/fnins.2020.614828 Text en Copyright © 2020 Reich and Hölscher. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Reich, Niklas Hölscher, Christian Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease |
title | Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease |
title_full | Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease |
title_fullStr | Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease |
title_full_unstemmed | Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease |
title_short | Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease |
title_sort | acylated ghrelin as a multi-targeted therapy for alzheimer's and parkinson's disease |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767977/ https://www.ncbi.nlm.nih.gov/pubmed/33381011 http://dx.doi.org/10.3389/fnins.2020.614828 |
work_keys_str_mv | AT reichniklas acylatedghrelinasamultitargetedtherapyforalzheimersandparkinsonsdisease AT holscherchristian acylatedghrelinasamultitargetedtherapyforalzheimersandparkinsonsdisease |